All news

Whitepaper: Tumor Mutational Burden (TMB)

The Tumor Mutational Burden (TMB) is a biomarker that shows the total number of somatic and coding mutations, base substitutions, insertions or measures deletions (indels) per megabase (Mb) of the examined genome. It must be validated individually for each indication. Strongly mutated tumors are more likely to generate neoantigens that are recognized as foreign by immune cells. Tumors with a high TMB can therefore have a high immunogenicity. Read more about why TMB is relevant in the context of cancer immunotherapy in our whitepaper: